BioPharm International on Cellipont and Xiogenix Partnership
This summary is based on the original article, which can be found here. Cellipont Bioservices, a contract development and manufacturing organization (CDMO) specializing in cell therapy manufacturing, has entered into a strategic partnership with Xiogenix, a...
Cellipont Bioservices Press Release Announces Partnership with Xiogenix
This summary is based on the original press release, which can be found here. Xiogenix, a leader in biopharmaceutical technology, is excited to announce a strategic partnership with Cellipont Bioservices, a premier cell therapy Contract Development and Manufacturing...
CAR-T Therapy: A Life-Changing Approach to Modern Medicine
In recent years, a remarkable revolution in cancer treatment has taken center stage, captivating the medical community and offering hope to millions of patients and their families. Chimeric Antigen Receptor T-cell therapy, commonly known as CAR-T therapy, has emerged...
Demineralization and Decellularization: The Vital Role in Regenerative Medicine
Demineralization and decellularization are two critical processes that have become indispensable in the field of regenerative medicine. Both techniques are pivotal in the development of advanced biomaterials and tissue engineering strategies. Demineralization and...
BreakThrU Strategies Unites the Forces of Ardent Animal Health and Xiogenix
BreakThru Strategies, a visionary parent company, has orchestrated a groundbreaking collaboration between two pioneering entities in the biomedical landscape - Ardent Animal Health and Xiogenix. The fusion of Ardent Animal Health's expertise in animal stem cell...
CONNECT WITH US
W160 S6550 Commerce Drive
Muskego, WI 53150
Copyright 2023 Xiogenix. All rights reserved.